Bruton tyrosine kinase
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der BTK gene provides instructions for making a protein called Bruton tyrosine kinase (BTK), which is essential for the development and maturation of B cells. B cells are specialized white blood cells that help protect the body against infection. These cells can mature into cells that produce special proteins called antibodies or immunoglobulins. Antibodies attach to specific foreign particles and germs, marking them for destruction. The BTK protein transmits important chemical signals that instruct B cells to mature and produce antibodies.
Normal function
Der BTK gene provides instructions for making a protein called Bruton tyrosine kinase (BTK), which is essential for the development and maturation of B cells. B cells are specialized white blood cells that help protect the body against infection. These cells can mature into cells that produce special proteins called antibodies or immunoglobulins. Antibodies attach to specific foreign particles and germs, marking them for destruction. The BTK protein transmits important chemical signals that instruct B cells to mature and produce antibodies.
Conditions referring to this gene or chromosome
Other names
AGMX1
AT
ATK
BPK
Bruton agammaglobulinemia tyrosine kinase
Bruton's tyrosine kinase
BTK_HUMAN
dominant-negative kinase-deficient Bruton's tyrosine kinase
IMD1
MGC126261
MGC126262
PSCTK1
tyrosine-protein kinase BTK
XLA
Related patient information and medicines

Patient information leaflet
Chronische myeloische Leukämie
Treatment for the initial chronic phase The aim of treatment is to control the disease process, to ease any symptoms and to prevent (or delay) the progress... You may be advised to have one or more of the following treatments: Imatinib tablets. This medicine is known as a tyrosine kinase inhibitor. The chemical tyrosine kinase is made by the.

Patient information leaflet
Mundkrebs
Dia... Dr Krishna Vakharia , 16th October 2023 The National Institute for Health and Care Excellence (NICE) has recommended that ein person should receive a diagnosis or ruling out of cancer within 28 days of being referred urgently by their GP for suspected cancer. To confirm the diagnosis It is likely that you will need a biopsy. Cetuximab is an.

Patient information leaflet
Mastozytose und Mastzellenerkrankungen
If the condition is severe, surgery to remove the spleen (splenectomy), medicines that have an effect on ... Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute for Health and Care Excellence (NICE) has brought out new guidance on the use of midostaurin for people with mastocytosis..

Patient information leaflet
Glykogenspeicherkrankheiten
Glykogenspeicherkrankheiten are a group of inherited diseases. They result from a problem with one of the proteins (known as enzymes) involved in the conversion of glucose to glycogen, or the breakdown of glycogen back into glucose. They mostly tend to affect your liver and muscles. Most are diagnosed in childhood. Symptoms include weakness,.

Patient information leaflet
Muskeldystrophie
If you or a family member have MD, you will usually be offered tests and specialist advice from a doctor who specialises in diagnosing genetic conditions (a geneticist). This can give more information about the particular 'faulty' gene and the exact type of MD that you have or that your relative has. MD may be diagnosed using one or more of the.

Patient information leaflet
Primärer Leberkrebs
Some conditions which cause persistent inflammation of the gut increase the risk slightly of developing an uncommon type of primary liver cancer (call. Smoking There is some evidence that smoking Smoking can increase the risk. There are new medicines being developed for the treatment of liver cancer. For example, sorafenib is a type of medicine.
Weiterführende Lektüre und Referenzen
- Bruton tyrosine kinase; MedlinePlus, National Library of Medicine.
- Alatzoglou KS, Dattani MT. Genetic causes and treatment of isolated growth hormone deficiency-an update. Nat Rev Endocrinol. 2010 Oct;6(10):562-76. doi: 10.1038/nrendo.2010.147.
- Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol. 2006 Feb-Mar;118(2-3):195-200. doi: 10.1016/j.clim.2005.10.007. Epub 2005 Nov 16.
- Conley ME, Farmer DM, Dobbs AK, Howard V, Aiba Y, Shurtleff SA, Kurosaki T. A minimally hypomorphic mutation in Btk resulting in reduced B cell numbers but no clinical disease. Clin Exp Immunol. 2008 Apr;152(1):39-44. doi: 10.1111/j.1365-2249.2008.03593.x. Epub 2008 Jan 28.
- Jyonouchi H, Geng L, Toruner GA, Vinekar K, Feng D, Fitzgerald-Bocarsly P. Monozygous twins with a microdeletion syndrome involving BTK, DDP1, and two other genes; evidence of intact dendritic cell development and TLR responses. Eur J Pediatr. 2008 Mar;167(3):317-21. doi: 10.1007/s00431-007-0493-0. Epub 2007 May 23.
- Maas A, Hendriks RW. Role of Bruton's tyrosine kinase in B cell development. Dev Immunol. 2001;8(3-4):171-81. doi: 10.1155/2001/28962.
- Richter D, Conley ME, Rohrer J, Myers LA, Zahradka K, Kelecic J, Sertic J, Stavljenic-Rukavina A. A contiguous deletion syndrome of X-linked agammaglobulinemia and sensorineural deafness. Pediatr Allergy Immunol. 2001 Apr;12(2):107-11. doi: 10.1034/j.1399-3038.2001.0129999107.x.
- Sediva A, Smith CI, Asplund AC, Hadac J, Janda A, Zeman J, Hansikova H, Dvorakova L, Mrazova L, Velbri S, Koehler C, Roesch K, Sullivan KE, Futatani T, Ochs HD. Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genes. J Clin Immunol. 2007 Nov;27(6):640-6. doi: 10.1007/s10875-007-9123-x. Epub 2007 Sep 12.
- Smith CIE, Berglof A. X-Linked Agammaglobulinemia. 2001 Apr 5 [updated 2024 Jun 27]. In: Adam MP, Bick S, Mirzaa GM, Wallace SE, Amemiya A, editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from http://www.ncbi.nlm.nih.gov/books/NBK1453/
- Valiaho J, Smith CI, Vihinen M. BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat. 2006 Dec;27(12):1209-17. doi: 10.1002/humu.20410.
- Wit JM, Kiess W, Mullis P. Genetic evaluation of short stature. Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):1-17. doi: 10.1016/j.beem.2010.06.007.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Feb 2012 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

